NCT04416100View on ClinicalTrials.gov

Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19)

UnknownOBSERVATIONAL
Enrollment

130

Participants

Timeline

Start Date

April 29, 2020

Primary Completion Date

April 28, 2022

Study Completion Date

April 28, 2022

Conditions
Covid-19Pulmonary Fibrosis
Interventions
DIAGNOSTIC_TEST

Pulmonary function tests

Spirometry or plethysmography, measurement of diffusion capacity

DIAGNOSTIC_TEST

Imaging

HRCT and echocardiography as scheduled within routine clinical examinations

BIOLOGICAL

Blood sampling

Standard laboratory test as part of routine clinical examination and collection of peripheral blood for immunofibrotic phenotyping

Trial Locations (1)

6020

RECRUITING

Medical University of Innsbruck, Innsbruck

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Medical University Innsbruck

OTHER

NCT04416100 - Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19) | Biotech Hunter | Biotech Hunter